A Clinical Study of the Safety and Efficacy of Universal CAR-T Cells Targeting CD19 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This is a single-center, single-arm, open-label clinical study, and the sample size is set to 3-6 subjects.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Willing to participate in this clinical study and sign an informed consent form;
• Age ≥ 18 years old;
• Estimated survival time ≥ 3 months;
• At least one measurable lesion;
• CD19 positively expressed;
• ECOG score 0-1；
• Hematology, coagulation and biochemistry parameters meeting the requirements;
• LVEF ≥ 55%;
• No severe pulmonary disorders;
Locations
Other Locations
China
Shanghi Tongji Hospital (Tongji Hospital of Tongji University)
RECRUITING
Shanghai
Contact Information
Primary
Ping Li, phD
13564181131
Time Frame
Start Date: 2025-03-11
Estimated Completion Date: 2028-03-11
Participants
Target number of participants: 6
Treatments
Experimental: Treatment group
5×10\^6/kgBW
Related Therapeutic Areas
Sponsors
Leads: Bioray Laboratories
Collaborators: Shanghai Tongji Hospital (Tongji Hospital of Tongji University)